Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-016571
Filing Date
2019-05-07
Accepted
2019-05-07 16:40:32
Documents
59
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q prnb-10q_20190331.htm 10-Q 2024946
2 EX-31.1 prnb-ex311_8.htm EX-31.1 17981
3 EX-31.2 prnb-ex312_6.htm EX-31.2 18021
4 EX-32.1 prnb-ex321_7.htm EX-32.1 16243
  Complete submission text file 0001564590-19-016571.txt   7181534

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT prnb-20190331.xml EX-101.INS 1819804
6 XBRL TAXONOMY EXTENSION SCHEMA prnb-20190331.xsd EX-101.SCH 41213
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE prnb-20190331_cal.xml EX-101.CAL 40539
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE prnb-20190331_def.xml EX-101.DEF 115207
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE prnb-20190331_lab.xml EX-101.LAB 321403
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prnb-20190331_pre.xml EX-101.PRE 249221
Mailing Address 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Business Address 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080 (650) 416-7700
Principia Biopharma Inc. (Filer) CIK: 0001510487 (see all company filings)

EIN.: 263487603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38653 | Film No.: 19803699
SIC: 2834 Pharmaceutical Preparations